2016-Therapy – Disease Modifying

36 months PANGAEA: A 5-year non-interventional Study of Safety, Efficacy and Pharmacoeconomic Data for Fingolimod Patients in Daily Clinical Practice

T. Ziemssen; H. Albrecht; J. Haas; L. Luisa Klotz; M. Lang; C. Lassek; S. Schmidt; B. Tackenberg; C. Cornelissen

Alemtuzumab-Treated Patients with Active Relapsing-Remitting Multiple Sclerosis Demonstrate Durable Slowing of Brain Volume Loss Over 5 Years with Most Not Receiving Treatment for 4 Years: Care-MS I and Ii Extension Study

Jihad Said Inshasi, Mohammed Al Jumah, Raed Alroughani, D Alasdair S Compston, Massimo Filippi, Gavin Giovannoni, Gavin Giovannoni, Eva Havrdova, Bassem Yamout, David H Margolin, Karthinathan Thangavelu

Compliance and Discontinuation Rates with Gilenya® and other Disease-modifying therapies: Canadian Real-world Experience.

Pierre Duquette, Michael Yeung, Robyn Schecter and Paola Haddad

Cutaneous Necrosis in an MS Patient Treated with Interferon-Beta-1a

Ahmet Çetiz, Şeref Demirkaya, Serdar Taşdemir

Early Clinical Efficacy of Fingolimod Compared with Interferon-beta-1a in Relapsing Multiple Sclerosis

Daniel Ontaneda, Barry Singer, Xiangyi Meng, Kathleen Hawker

Effect of Natalizumab On Disease Activity in Relapsing Remitting Multiple Sclerosis Patients.

Mabroka.I.M.Agiela

Effects of Enhanced Environment and Induced Depression On Cuprizone Mouse Model of Demyelination

Hawra Faisal Mansoor Alalwan, Reem Merza Abdulla, Zahra S.Ali Almosawi, Amal Fuad Almahroos, Ayman Merza Mohamed, Fajer Alammadi, Fajer Alammadi, Ahmed Yaqoob Almahrezi, Amer Alansari

Efficacy and Safety Profile of Teriflunomide in The Treatment of Multiple Sclerosis. Experience from A Tertiary MS Center in Dubai

Pournamy Sarathchandran, Yasmine Kamal Mohamed, Jihad Said Inshasi, Suhail Alrukn, Abubaker Al Madani

Efficacy of Delayed-Release Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis in Prior Interferon Users with Low Clinical Disease Activity: Integrated Analysis of the Phase 3 Define and Confirm Studies

Oscar Fernandez,Gavin Giovannoni, Robert J. Fox, Ralf Gold, J. Theodore Phillips, James Potts, Jing L. Marantz

Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis Using a Composite Measure of Disability: Integrated Analysis of the Phase 3 Define and Confirm Studies

J.Theodore Phillips, Amit Bar-Or, Ralf Gold, Gavin Giovannoni, Robert J. Fox, James Potts, Jing L. Marantz

Efficacy of Fingolimod on NEDA-4 in Pooled FREEDOMS and FREEDOMS II Studies by Subgroups of Baseline Characteristics

Mark S Freedman, Ludwig Kappos, Bruce A. C. Cree, Ernst-Wilhelm Radue, Gavin Giovannoni, Shannon Ritter, Daniela Piani Meier, Davorka Tomic

Estimation of Brain Volume Loss with Multiple Imputation of Missing Values in the Placebo Controlled FREEDOMS Trials of Fingolimod

G. Cutter, X. Meng , M.Z. Islam, B. Brown

Evaluation of Plasma Level of Brain-Derived Neurotrophic Factor and Interleukin-6 In Relapsing-Remitting Multiple Sclerosis Patients Compared to Healthy Subjects

Mansour Shajarian, Masoud Etemadifar, Fereshteh Alsahebfosoul

Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis: The Real World Experience at Rashid Hospital MS Center in Dubai

Jihad Said Inshasi, Pournamy Sarathchandran, Ayman Alboudi, Yasmine Kamal

Impact of Discontinuing Beta-Interferon in Patients with Relapsing Remitting Multiple Sclerosis

Mabroka.I.M.Agiela

Interim Analysis of the START Study – Extensive Electrocardiographic Monitoring Confirms the Good Cardiac Safety Profile of Fingolimod

Volker Limmroth, Wilhelm Haverkamp, Ralf Dechend, Michael Lang, Judith Haas, Bert Wagner, Stephan Richter, Heinke Schieb, Tjalf Ziemssen

Long-term Effects of Fingolimod on NEDA by Year of Treatment

Bruce A. C. Cree, Ludwig Kappos, Mark S. Freedman, Jeffrey A. Cohen, Till Sprenger, Shannon Ritter, Davorka Tomic, Daniela Piani Meier

Long-term Efficacy, Safety, tolerability and Quality of Life with Fingolimod Treatment in Patients with Multiple Sclerosis in Real-world Settings in France: VIRGILE Study Design

M. Coustans, M. Debouverie, G. Kobelt, C. LebrunFrenay, E. Leray, C. Papeix, J.M. Visy, L. Willemin, B. Allaf

Long-term Safety and Effectiveness of Fingolimod: 7 year Data from the LONGTERMS Study

L. Kappos, J. Cohen, K. Selmaj, R. Gottschalk, A. Pradhan, Y. Chen, N. Putzki

Meta-analysis of Randomized Placebo Control Trials in Multiple Sclerosis

A. Abulaban, H. Tamimi, L. Tuleimat, A. Al-Dalati, I. AlabdulRazzak, M. Alkhawajah

No Evidence of an Increased Risk for Malignancy Associated with Natalizumab Therapy in 9 Years of Postmarketing Surveillance

Cynthia Carrillo-Infante, Sarah Gheuens, Made Wenten, Pei-Ran Ho, Irene Koulinska, Sandra Richman

Patients with Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy Demonstrate Durable Improvements in Clinical Outcomes with Alemtuzumab: 5-Year Follow-Up of Care-MS Ii

Raed Alroughani, Mohamed Al Jumah, Douglas L Arnold, Hans-Peter Hartung, Eva Havrdova, Jihad Said Inshasi, Jihad Said Inshasi, David H Margolin, Linda Kasten, D Alasdair S Compston

MENACTRIMS ONLINE LIBRARY